Market Technicals Simplified: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories

 Market Technicals Simplified: Inovio Pharma, Sequenom, Nektar Therapeutics,
                          and Discovery Laboratories

PR Newswire

LONDON, January 16, 2014

LONDON, January 16, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Wednesday, January 15, 2014, the U.S. equity market advanced, as the S&P
500 ended the day at1,848.38, up 0.52%; the Dow Jones Industrial Average
closed at 16,481.94, up 0.66%; and the NASDAQ Composite finished at4,214.88,
up 0.76%. The S&P 500 Health Care Sector Index edged 0.14% lower to close the
session at 659.40; and the same has gained 6.17% in the last one month and
11.06% in the previous three months, outperforming the S&P 500, which has
gained 4.12% and 8.85% during the respective periods. The major movers in the
Health Care Sector includedInovio Pharmaceuticals Inc. (NYSE MKT: INO),
Sequenom Inc. (NASDAQ: SQNM), Nektar Therapeutics (NASDAQ: NKTR), and
Discovery Laboratories Inc. (NASDAQ: DSCO). All these companies are tracked by
AAAResearchReports.com. Free technical research on INO, SQNM, NKTR, and DSCO
can be downloaded upon signing up at:

http://www.aaaresearchreports.com/register/ 

Inovio Pharmaceuticals Inc.'s stock edged 0.41% lower on Wednesday, even as
the broader market posted gains. The company's shares ended the day at $2.44,
after oscillating between $2.40 and $2.50 during the trading session. A total
of 2.42 million shares were traded, which is below the daily average volume
4.30 million. Despite Wednesday's decline, the company's shares have surged
28.42% in the previous three months and 23.23% in the last one month,
outperforming the S&P 500, which has gained 8.85% and 4.12% during the
respective periods. Moreover, Inovio Pharmaceuticals Inc.'s stock is trading
above its 50-day and 200-day moving averages of $2.19 and $1.54, respectively.
Sign up and read the complimentary report on INO at:

http://www.AAAResearchReports.com/INO011614.pdf

Sequenom Inc.'s stock surged on Wednesday, closing the day at $2.74, up 6.20%
from the previous day's closing price of $2.58. The company's shares
vacillated between $2.56 and $2.78 during the trading session. A total of 3.00
million shares were traded, which is above the daily average volume of 2.90
million. The company's shares have gained 28.64% in the previous one month and
5.38% in the last three trading sessions, outperforming the S&P 500, which has
gained 4.12% and 0.33% during the respective periods. Additionally, Sequenom
Inc.'s stock is trading above its 50-day moving average of $2.34. The free
report on SQNM can be downloaded by signing up now at:

http://www.AAAResearchReports.com/SQNM011614.pdf

Shares in Nektar Therapeutics advanced 0.23% on Wednesday, finishing the day
at $13.16, after fluctuating between $12.96 and $13.32 during the trading
session. A total of 0.68 million shares were traded, which is below the daily
average volume of 0.81 million. The company's shares have surged 24.98% in the
previous one month and 37.37% in the last three months, outperforming the S&P
500, which has gained 4.12% and 8.85% during the respective periods. Further,
Nektar Therapeutics's stock is trading above its 50-day and 200-day moving
averages of $11.29 and $11.15, respectively. A free report on NKTR can be
accessed by registering at:

http://www.AAAResearchReports.com/NKTR011614.pdf

On Wednesday, shares in Discovery Laboratories Inc. surged 4.55%, ending the
day at $2.53, after vacillating between $2.43 and $2.56 during the trading
session. A total of 1.01 million shares were traded on Wednesday, which is
above the daily average volume of 0.72 million. Discovery Laboratories Inc.'s
shares have gained 4.12% in the previous three trading sessions and 19.91% in
the last one month, outperforming the S&P 500, which has gained 0.33% and
4.12% during the respective periods. Furthermore, the company's stock is
trading above its 50-day and 200-day moving averages of $2.21 and $1.93,
respectively. Register with AAA Research Reports and download research on DSCO
for free at:

http://www.AAAResearchReports.com/DSCO011614.pdf

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AAAResearchReports.com/

SOURCE AAA Research Reports

Contact: Contact Name: Peter F. Jones - Phone #: +1(646)396-9126, Email ID:
info@aaaresearchreports.com